bms-582949
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00162292)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Active metabolite of prodrug BMS-751324
Chemistry & pharmacology
Loading structure…
SMILES
CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C- Mol. weight
- 406.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1230065 ↗
Also known as
- 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-n-propylpyrrolo(1,2-f)(1,2,4)triazine-6-carboxamide
- bms582949
- bms 582949
- bms-582949
- bms-582949
- bms-582949
- bms-582949
- bms-582949
- ps540446
- ps 540446
- ps-540446
- ps-540446
- ps-540446
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00570752 | Phase 2 | Dec 1, 2008 | Bristol-Myers Squibb |
| NCT00605735 | Phase 2 | Mar 1, 2008 | Bristol-Myers Squibb |
| NCT00399906 | Phase 2 | Aug 1, 2007 | Bristol-Myers Squibb |
| NCT00162292 | Phase 1 | Nov 1, 2005 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 2 | 2005 |
1 organizations
Page 1 / 1